ArticleFrontiers in endocrinology2026
Hydrogen sulfide donor sodium hydrosulfide modulates ovarian steroidogenesis and follicular integrity in a DHEA-induced rat model of polycystic ovary syndrome.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hydrogen sulfide (H Methods: Thirty adult female Wistar rats were randomly assigned to control, vehicle, PCOS, NaHS, and PCOS+NaHS groups (n=6 each). PCOS was induced by daily subcutaneous injections (s.c) of DHEA (6 mg/100 g body weight) for 20 days. NaHS (200 μg/kg/day) was administered intraperitoneally (i.p.), either alone or in combination with DHEA. Serum hormone levels were analyzed, estrous cyclicity was tracked, and ovarian tissues were examined histologically for follicular development, apoptosis, and the expression of key steroidogenic enzymes (StAR, 3β-HSD, CYP19A1) and H Results: DHEA treatment resulted in disrupted estrous cyclicity, elevated serum estradiol and progesterone levels, reduced numbers of primordial, primary, Graafian follicles and corpora lutea, and increased cystic and atretic follicles. Apoptotic activity and the expression of StAR, 3β-HSD, and CYP19A1 were significantly elevated, whereas CBS and CTH expression levels were reduced. NaHS administration attenuated DHEA-induced alterations by improving estrous cyclicity, reducing follicular damage and apoptosis, downregulating steroidogenic enzyme overexpression, and partially restoring CBS and CTH expression. Conclusions: Pharmacological supplementation with the H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.